{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:00:48Z","timestamp":1780138848548,"version":"3.54.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01504-z","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T10:02:58Z","timestamp":1780135378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Modified GTX as Second-Line Therapy in Advanced Pancreatic Adenocarcinoma: A Prospective Cohort Study"],"prefix":"10.1007","volume":"57","author":[{"given":"Sara El","family":"Meski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Al Tartir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mezher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Temraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"1","key":"1504_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1504_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1478-7954-12-4","volume":"12","author":"A Shamseddine","year":"2014","unstructured":"Shamseddine A, et al. Cancer trends in Lebanon: a review of incidence rates for the period of 2003\u20132008 and projections until 2018. Popul Health Metrics. 2014;12(1):4.","journal-title":"Popul Health Metrics"},{"issue":"19","key":"1504_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"1504_CR4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403\u201313.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1504_CR5","doi-asserted-by":"publisher","first-page":"11675","DOI":"10.1038\/s41598-025-96157-6","volume":"15","author":"Y Sezgin","year":"2025","unstructured":"Sezgin Y, et al. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. Sci Rep. 2025;15(1):11675.","journal-title":"Sci Rep"},{"issue":"10018","key":"1504_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"key":"1504_CR7","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1200\/jco.2009.27.15_suppl.4623","volume":"27","author":"RL Fine","year":"2009","unstructured":"Fine RL, et al. Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol. 2009;27 Suppl 15:4623. https:\/\/doi.org\/10.1200\/jco.2009.27.15_suppl.4623","journal-title":"J Clin Oncol"},{"issue":"4","key":"1504_CR8","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4(4):1013\u20139.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/jcc.20054","volume":"25","author":"S Pereira","year":"2004","unstructured":"Pereira S, Fernandes PA, Ramos MJ. Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. J Comput Chem. 2004;25(10):1286\u201394.","journal-title":"J Comput Chem"},{"key":"1504_CR10","unstructured":"Mezher M, Mezher D. Second-line modified GTX versus Gemcitabine-Nab-Paclitaxel (GmAb) following first-line FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis at the American University of Beirut Medical Center (AUBMC). 2023;14:550\u20138."},{"issue":"2","key":"1504_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-010-1329-6","volume":"67","author":"O Katopodis","year":"2011","unstructured":"Katopodis O, et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol. 2011;67(2):361\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jphs.2015.01.006","volume":"127","author":"K Minami","year":"2015","unstructured":"Minami K, et al. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. J Pharmacol Sci. 2015;127(3):319\u201325.","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"1504_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"1504_CR14","doi-asserted-by":"publisher","first-page":"p2290120","DOI":"10.1155\/2021\/2290120","volume":"2021","author":"G D\u2019Arrigo","year":"2021","unstructured":"D\u2019Arrigo G, et al. Methods to Analyse Time-to-Event Data: The Kaplan-Meier Survival Curve. Oxid Med Cell Longev. 2021;2021:p2290120.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"1504_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12029-013-9571-x","volume":"45","author":"H Ajouz","year":"2014","unstructured":"Ajouz H, et al. Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma. J Gastrointest Cancer. 2014;45(1):109\u201312.","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"1504_CR16","first-page":"115","volume":"6","author":"H Dbouk","year":"2013","unstructured":"Dbouk H, et al. Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Gastrointest Cancer Res. 2013;6(4):115\u20137.","journal-title":"Gastrointest Cancer Res"},{"issue":"Suppl 2","key":"1504_CR17","doi-asserted-by":"publisher","first-page":"ii94","DOI":"10.1093\/annonc\/mdw201.36","volume":"27","author":"S Temraz","year":"2016","unstructured":"Temraz S, et al. RM-037: Modified GTX second-line therapy in pancreatic adenocarcinoma. Ann Oncol. 2016;27(Suppl 2):ii94\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdw201.36.","journal-title":"Ann Oncol"},{"issue":"2","key":"1504_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00280-011-1705-x","volume":"69","author":"HK Dakik","year":"2012","unstructured":"Dakik HK, et al. The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2012;69(2):425\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1504_CR19","doi-asserted-by":"crossref","unstructured":"Chen Y, Qi Y, Wang K. Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress. Front Oncol. 2023;13.","DOI":"10.3389\/fonc.2023.1169010"},{"issue":"30","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1002\/chem.200700260","volume":"13","author":"NM Cerqueira","year":"2007","unstructured":"Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry. 2007;13(30):8507\u201315.","journal-title":"Chemistry"},{"issue":"2 Suppl 3","key":"1504_CR21","first-page":"215","volume":"19","author":"H Wilke","year":"1992","unstructured":"Wilke H, et al. Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. Semin Oncol. 1992;19(2 Suppl 3):215\u20139.","journal-title":"Semin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01504-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01504-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01504-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T10:03:00Z","timestamp":1780135380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01504-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01504-z","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"131"}}